1
Home
Companies

Kinnate Biopharma

#7439

Rank

$124.99M

Marketcap

US United States

Country

Kinnate Biopharma
Leadership team

Mr. Nima Farzan M.B.A. (Pres, CEO & Director)

Ms. Neha Krishnamohan (CFO, Principal Accounting Officer and Exec. VP of Corp. Devel.)

Mr. Mark A. Meltz (COO, Gen. Counsel, Treasurer & Sec.)

Products/ Services
Biopharma, Biotechnology, Health Care, Medical, Therapeutics
Number of Employees
50 - 100
Headquarters
San Diego, California, United States
Established
2018
Company Registration
SEC CIK number: 0001797768
Traded as
KNTE
Social Media
URL
https://www.kinnate.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
History

Kinnate Biopharma was founded in 2019 as a spin-off from the Johns Hopkins University School of Medicine. We strive to build a diverse and collaborative team, and are committed to advancing science and medicine.

Mission
Our mission is to revolutionize and accelerate the discovery, development and delivery of novel therapies for cancer and autoimmune diseases by pushing the frontiers of molecular biology, biotechnology and data science.
Vision
Our vision is to increase and speed up access to lifesaving treatments, empower patientsn and foster innovation in the life science space.
Key Team

Ms. Priyanka Shah (VP of Investor Relations & Communications)

Ms. Barbara Warren (VP of People & Culture)

Dr. Richard Thomas Williams MBBS, Ph.D. (Chief Medical Officer)

Dr. Robert Kania Ph.D. (Sr. VP of Drug Discovery)

Mr. Jason Hampson M.D. (VP and Head of Regulatory Affairs & Quality)

Recognition and Awards
Kinnate Biopharma has been recognized as one of the top 50 emerging biotechnology companies by B&T Magazine, and has earned several awards including the Rising Stars Award from the National Institutes of Health and the Maryland Life Sciences Outstanding BioTech Award.
References

https://www.investing.com/equities/kinnate-biopharma-inc

https://finance.yahoo.com/quote/KNTE/profile?p=KNTE

https://www.crunchbase.com/organization/kinnate-biopharma

https://companiesmarketcap.com/

https://www.kinnate.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Kinnate Biopharma
Leadership team

Mr. Nima Farzan M.B.A. (Pres, CEO & Director)

Ms. Neha Krishnamohan (CFO, Principal Accounting Officer and Exec. VP of Corp. Devel.)

Mr. Mark A. Meltz (COO, Gen. Counsel, Treasurer & Sec.)

Products/ Services
Biopharma, Biotechnology, Health Care, Medical, Therapeutics
Number of Employees
50 - 100
Headquarters
San Diego, California, United States
Established
2018
Company Registration
SEC CIK number: 0001797768
Traded as
KNTE
Social Media
URL
https://www.kinnate.com